Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Madrigal Pharmaceuticals ...

    NASDAQ: MDGL · Real-Time Price · USD
    425.08
    12.85 (3.12%)
    At close: Aug 26, 2025, 3:59 PM
    435.00
    2.33%
    After-hours: Aug 26, 2025, 07:03 PM EDT
    3.12%
    Bid 418.5
    Market Cap 9.47B
    Revenue (ttm) 515.55M
    Net Income (ttm) -281.9M
    EPS (ttm) -12.65
    PE Ratio (ttm) -33.6
    Forward PE 95.87
    Analyst Strong Buy
    Ask 432
    Volume 384,430
    Avg. Volume (20D) 370,530
    Open 412.69
    Previous Close 412.23
    Day's Range 412.19 - 426.73
    52-Week Range 200.63 - 426.73
    Beta -1.03

    About MDGL

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol MDGL
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for MDGL stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Next Earnings Release

    Madrigal Pharmaceuticals Inc. is scheduled to release its earnings on Oct 30, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    3 weeks ago
    +8.59%
    Madrigal Pharmaceuticals shares are trading higher... Unlock content with Pro Subscription
    1 month ago
    +10.87%
    Madrigal Pharmaceuticals shares are trading higher after the company received a Notice of Allowance from the US Patent and Trademark Office for a new patent covering Rezdiffra.
    news image

    1 week ago · zacks.com

    Madrigal Gets Conditional Nod for MASH Drug Rezdiffra in EU

    MDGL wins EU nod for Rezdiffra as the first and only approved MASH therapy. The drug's launch in Europe is expected in the fourth quarter of 2025.

    news image

    1 week ago · seekingalpha.com

    Madrigal Pharmaceuticals: A High-Paced Launch That Could Grow Further

    Rezdiffra's Q2 '25 net sales surged 55% to $212.8M, beating expectations and highlighting strong commercial momentum for Madrigal Pharmaceuticals, Inc. Despite robust revenue growth, Madrigal Pharmace...

    2 weeks ago · youtube.com

    Madrigal Pharmaceuticals CEO: We're positioned for decades of growth

    Bill Sibold, Madrigal Pharmaceuticals CEO, joins 'Fast Money' to discuss Q2 earnings results, the weight loss space and their GLP-1 strategy.

    news image

    3 weeks ago · seekingalpha.com

    Madrigal Pharmaceuticals, Inc. (MDGL) Q2 2025 Earnings Call Transcript

    Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL ) Q2 2025 Earnings Conference Call August 5, 2025 8:00 AM ET Company Participants David Soergel - Executive VP & Chief Medical Officer Mardi C. Dier - Execu...

    news image

    3 weeks ago · zacks.com

    Madrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates

    Madrigal (MDGL) came out with a quarterly loss of $1.9 per share versus the Zacks Consensus Estimate of a loss of $3.48. This compares to a loss of $7.1 per share a year ago.

    news image

    3 weeks ago · seekingalpha.com

    Madrigal Pharmaceuticals: Rezdiffra Expansion Avenues Shift Focus To Long Term

    Madrigal Pharmaceuticals, Inc.'s Rezdiffra showed strong Q1 2025 sales of $137.3M that highlight robust U.S. demand and early commercial momentum in non-cirrhotic NASH patients. Key catalysts include ...

    news image

    1 month ago · zacks.com

    MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights

    Madrigal Pharmaceuticals stock jumps 11% after securing a new U.S. patent for Rezdiffra's dosing, reinforcing exclusivity through 2044.

    news image

    1 month ago · zacks.com

    Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?

    Madrigal (MDGL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

    news image

    2 months ago · marketwatch.com

    Madrigal Pharmaceuticals Gets CHMP Backing for Rezdiffra Approval

    Madrigal Pharmaceuticals said the European Medicines Agency's Committee for Medicinal Products for Human Use has recommended approval of its Rezdiffra treatment for adults with the liver disease nonci...

    Add to Watchlist